RxDoctor Payments Data

Dudley Goulden, MD

Cardiovascular Disease · Tyler, TXNPI 1336138742

Payments from drug & device makers

$7,157in general payments, 2019–2025

Across 233 payments — averaging $30.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$3K
  • Novartis$643
  • Merck$639
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$533
  • Pfizer$415
  • E.r. Squibb & Sons, L.L.C.$405
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,50799%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,157 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$67,904
Medicare patients
802
Services billed
1,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$194,545
JardianceEmpagliflozin61$63,332
EntrestoSacubitril/Valsartan46$37,857
FarxigaDapagliflozin Propanediol31$25,640
XareltoRivaroxaban29$19,408
BrilintaTicagrelor26$13,271
Metoprolol Succinate222$2,657
Losartan Potassium192$1,773
Potassium Chloride92$1,284
Nitroglycerin40$1,198
Atorvastatin Calcium146$1,166
Amlodipine Besylate209$1,165
Rosuvastatin Calcium122$1,068
Bumetanide35$1,054
ClopidogrelClopidogrel Bisulfate105$946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$415$194,545213 claims
Boehringer IngelheimJardiance$3,433$63,33261 claims
AstraZenecaFarxiga, Brilinta$171$38,91157 claims
NovartisEntresto$643$37,85746 claims
Johnson & JohnsonXarelto$106$19,40829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →